Barclays Forecasts Strong Price Appreciation for Humana (NYSE:HUM) Stock

Humana (NYSE:HUM) had its target price boosted by research analysts at Barclays from $250.00 to $253.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the insurance provider’s stock. Barclays‘s price target indicates a potential downside of 3.03% from the stock’s previous close.

A number of other brokerages also recently issued reports on HUM. Royal Bank of Canada cut their price objective on shares of Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Truist Financial decreased their price target on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a research note on Friday, October 11th. KeyCorp started coverage on shares of Humana in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. Oppenheimer lowered their price objective on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. Finally, Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and reduced their target price for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $315.48.

Humana Stock Down 2.0 %

Shares of HUM stock traded down $5.41 on Thursday, hitting $260.91. The stock had a trading volume of 1,168,064 shares, compared to its average volume of 1,854,947. The business has a 50 day moving average price of $300.84 and a 200 day moving average price of $335.23. Humana has a one year low of $213.31 and a one year high of $527.18. The company has a market cap of $31.44 billion, a PE ratio of 16.35, a P/E/G ratio of 2.04 and a beta of 0.50. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. Research analysts anticipate that Humana will post 16.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

Large investors have recently bought and sold shares of the business. Creative Financial Designs Inc. ADV lifted its position in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the last quarter. CarsonAllaria Wealth Management Ltd. boosted its position in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the period. Atwood & Palmer Inc. purchased a new position in Humana during the 3rd quarter worth approximately $29,000. Your Advocates Ltd. LLP lifted its stake in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the last quarter. Finally, Hantz Financial Services Inc. acquired a new position in shares of Humana in the 2nd quarter valued at $35,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.